Want to see IN:GLAND full AI Analyst Report?

Gland Pharma Ltd. (GLAND) Price & Analysis

1 Followers

GLAND Stock Chart & Stats

₹1713.95

-₹19.65(-1.06%)

At close: Jan 09 4:00 PM EST

₹1713.95

-₹19.65(-1.06%)

Day’s Range― - ―

52-Week Range₹1,575.00 - ₹2,529.30

Previous CloseN/A

Volume93.91K

Average Volume (3M)9.08K

Market Cap

₹403.41B

Enterprise Value₹331.76B

Total Cash (Recent Filing)₹27.04B

Total Debt (Recent Filing)₹3.02B

Price to Earnings (P/E)39.2

Beta0.65

Next Earnings

Aug 11, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend Yield1.07%

Share Statistics

EPS (TTM)47.97

Shares Outstanding164,959,690

10 Day Avg. Volume10,062

30 Day Avg. Volume9,084

Financial Highlights & Ratios

PEG Ratio0.58

Price to Book (P/B)2.70

Price to Sales (P/S)4.35

P/FCF Ratio37.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,080.00

Price Target Upside21.36% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)74.19

Revenue Forecast (FY)₹73.47B

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetExtremely low leverage and a large equity base give durable financial flexibility. This supports capital spending on sterile capacity, cushions against pricing or demand shocks, and enables opportunistic M&A or R&D funding without stressing liquidity over the next several months.

Improving Cash GenerationMarked improvement in operating and free cash flow strengthens internal funding for capex, debt servicing, and partnerships. Better cash generation reduces reliance on external financing and underpins sustainable investment in sterile injectables capacity and product filings.

Specialized Sterile-injectables CDMO ModelA clear specialization in sterile injectables and CDMO services creates high barriers to entry, technical know-how, and long-term customer relationships. This structural positioning supports recurrent contract revenues and premium pricing from regulated-market clients.

Bears Say

Gross Margin VolatilityA dramatic fall in gross margin signals potential cost, mix, or pricing pressures that weaken earnings durability. If structural, this reduces free cash flow potential and makes long-term revenue growth less effective at boosting profits or funding reinvestment.

Profitability Lag Versus Prior PeakRevenue growth without commensurate net income recovery suggests margin compression or one-off items. Persisting below-peak profitability limits ROE expansion and could constrain investor returns and reinvestment capability if not resolved structurally.

Moderate Cash ConversionBelow-par cash conversion reduces the amount of accounting profit that converts to usable cash. This limits resilience to shocks, reduces available internal funding for capacity or filings, and means earnings gains may not fully translate into stronger balance sheet metrics.

Gland Pharma Ltd. News

Gland Pharma Schedules Analyst and Institutional Investor Meetings

Gland Pharma Ltd. ( ($IN:GLAND) ) has provided an announcement. Gland Pharma Ltd. has notified stock exchanges that...

11d ago

GLAND

Gland Pharma Seeks Shareholder Nod to Reappoint Independent Director via E-Voting

An announcement from Gland Pharma Ltd. ( ($IN:GLAND) ) is now available. Gland Pharma has initiated a postal...

3M ago

GLAND

Gland Pharma Schedules Investor Meet Arranged by Goldman Sachs

Gland Pharma Ltd. ( ($IN:GLAND) ) just unveiled an update. Gland Pharma Limited has notified the stock exchanges...

4M ago

GLAND

Gland Pharma Schedules Series of Investor and Analyst Meetings in February 2026

Gland Pharma Ltd. ( ($IN:GLAND) ) just unveiled an announcement. Gland Pharma Limited has announced a series of...

5M ago

GLAND

Gland Pharma uploads Q3 FY26 earnings call recording for investors

An announcement from Gland Pharma Ltd. ( ($IN:GLAND) ) is now available. Gland Pharma Limited has notified the...

5M ago

GLAND

Gland Pharma Schedules Investor Meetings for November 2025

Gland Pharma Ltd. ( ($IN:GLAND) ) has shared an update. Gland Pharma Limited has announced a series of...

8M ago

GLAND

Gland Pharma Appoints New Secretarial Auditors to Strengthen Governance

Gland Pharma Ltd. ( ($IN:GLAND) ) has issued an announcement. Gland Pharma Limited has announced the appointment of...

10M ago

GLAND

Gland Pharma Updates RTA Contact Details Following Rebranding

Gland Pharma Ltd. ( ($IN:GLAND) ) just unveiled an announcement. Gland Pharma Limited has announced a change in...

1y ago

GLAND

Gland Pharma Receives SEBI Compliance Certificate for Q1 2025

An update from Gland Pharma Ltd. ( ($IN:GLAND) ) is now available. Gland Pharma Limited has announced the...

1y ago

GLAND

Gland Pharma Announces Trading Window Closure Ahead of Financial Results

Gland Pharma Ltd. ( ($IN:GLAND) ) has issued an update. Gland Pharma Limited has announced the closure of...

1y ago

GLAND

GLAND FAQ

What was Gland Pharma Ltd.’s price range in the past 12 months?

Gland Pharma Ltd. lowest stock price was ₹1575.00 and its highest was ₹2529.30 in the past 12 months.

What is Gland Pharma Ltd.’s market cap?

Gland Pharma Ltd.’s market cap is ₹403.41B.

When is Gland Pharma Ltd.’s upcoming earnings report date?

Gland Pharma Ltd.’s upcoming earnings report date is Aug 11, 2026 which is in 39 days.

How were Gland Pharma Ltd.’s earnings last quarter?

Gland Pharma Ltd. released its earnings results on May 15, 2026. The company reported ₹22.3 earnings per share for the quarter, beating the consensus estimate of ₹16.252 by ₹6.048.

Is Gland Pharma Ltd. overvalued?

According to Wall Street analysts Gland Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gland Pharma Ltd. pay dividends?

Gland Pharma Ltd. pays a Notavailable dividend of ₹20 which represents an annual dividend yield of 1.07%. See more information on Gland Pharma Ltd. dividends here

What is Gland Pharma Ltd.’s EPS estimate?

Gland Pharma Ltd.’s EPS estimate is 17.

How many shares outstanding does Gland Pharma Ltd. have?

Gland Pharma Ltd. has 164,959,690 shares outstanding.

What happened to Gland Pharma Ltd.’s price movement after its last earnings report?

Gland Pharma Ltd. reported an EPS of ₹22.3 in its last earnings report, beating expectations of ₹16.252. Following the earnings report the stock price went down -1.48%.

Which hedge fund is a major shareholder of Gland Pharma Ltd.?

Currently, no hedge funds are holding shares in IN:GLAND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gland Pharma Ltd.

Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Gland Pharma Ltd. (GLAND) Earnings & Revenues

Historic Earnings Reports

GLAND Stock 12 Month Forecast

Average Price Target

₹2,080.00

▲(21.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1705":"₹1,705","2464":"₹2,464","1894.75":"₹1,894.8","2084.5":"₹2,084.5","2274.25":"₹2,274.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.08K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1705,1894.75,2084.5,2274.25,2464],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2463.15,2433.6769230769232,2404.2038461538464,2374.7307692307695,2345.257692307692,2315.7846153846153,2286.3115384615385,2256.8384615384616,2227.3653846153848,2197.892307692308,2168.419230769231,2138.9461538461537,2109.473076923077,{"y":2080,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2463.15,2433.6769230769232,2404.2038461538464,2374.7307692307695,2345.257692307692,2315.7846153846153,2286.3115384615385,2256.8384615384616,2227.3653846153848,2197.892307692308,2168.419230769231,2138.9461538461537,2109.473076923077,{"y":2080,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2463.15,2433.6769230769232,2404.2038461538464,2374.7307692307695,2345.257692307692,2315.7846153846153,2286.3115384615385,2256.8384615384616,2227.3653846153848,2197.892307692308,2168.419230769231,2138.9461538461537,2109.473076923077,{"y":2080,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1859.38,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1960.93,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1868.8,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1980.55,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1929.5,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1726.2,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1715.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1897.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1795.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1706.65,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1751,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2292.5,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2463.15,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >